Ashkon Software



NDRM - NeuroDerm Ltd.

NeuroDerm Ltd. logo NeuroDerm Ltd. (NDRM) is a pharmaceutical company focused on developing and commercializing drug-device combinations for the treatment of central nervous system (CNS) disorders, such as Parkinson's disease, Alzheimer's disease, and schizophrenia. The company's product candidates are designed to address significant unmet medical needs by delivering drugs through continuous subcutaneous administration, which may provide more consistent drug levels and improved efficacy compared to current oral or injection therapies.

NeuroDerm's lead product candidate is ND0612, a levodopa/carbidopa liquid formulation that is delivered continuously through a subcutaneous patch pump. ND0612 is being developed for the treatment of Parkinson's disease and is currently in Phase III clinical trials. The company's other product candidates include ND0701, a combination therapy for the treatment of Alzheimer's disease, and ND0801, a combination therapy for the treatment of schizophrenia.

NeuroDerm was founded in 2003 and is headquartered in Rehovot, Israel. The company went public on the NASDAQ Global Mark




Copyright © 2000-2024, Ashkon Software LLC
Privacy Policy | Refund Policy | Disclaimer